Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMX-001 with RT and TMZ in High Grade Glioma
NCT02655601Phase 2Completed
- Sponsor
- BioMimetix
- Start
- Sep 2018
- Primary completion
- Aug 2023
- Modality
- Orthosteric Ligands, Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of manganese butoxyethyl pyridyl porphyrin in high-grade glioma (HGG), glioblastoma (GBM) and astrocytoma (2 arms), sponsored by BioMimetix. Primary endpoints: Maximum Tolerated Dose at 16 weeks and Overall Survival at 5 years. Started Sep 2018; status: completed.
02
Drugs
manganese butoxyethyl pyridyl porphyrin
03
Conditions
high-grade glioma (HGG)glioblastoma (GBM)astrocytoma
Beyond the preview
Go deeper on NCT02655601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02655601.